Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck's (MRK) Winrevair is poised to become the first activin signaling inhibitor therapy for PAH in Europe if approved by the European Commission.

Merck (MRK) Gets CHMP Nod for PAH Drug Winrevair in Europe

Chevron

Lockheed Martin

Altria

Newmont Mining

AT&T

Vale S.A.

In a portfolio, it's generally growth stocks that grab the limelight. Being high-beta stocks, the price action keeps investors on the edge.

7 Quiet Blue-Chip Stocks on the Verge of a Big Breakout Rally

Merck's (MRK) vaccine, Capvaxive, gets unanimous recommendation by a CDC committee for adults aged 65 years and older for pneumococcal vaccination and those with certain other underlying conditions.

Merck's (MRK) New Pneumococcal Jab Capvaxive Gets CDC Panel Vote

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Receives Positive EU CHMP Opinion for WINREVAIR™ (sotatercept) in Pulmonary Arterial Hypertension (PAH).

Merck Receives Positive EU CHMP Opinion for WINREVAIR™ (sotatercept) in Pulmonary Arterial Hypertension (PAH)

Dublin, June 28, 2024 (GLOBE NEWSWIRE) -- The "Bioreactors Market: Industry Trends and Global Forecasts, till 2035 - Distribution by Fabrication Material, Type of Bioprocess, Type of Biologic, and Key Geographical Regions" report has been added to ResearchAndMarkets.com's offering.

Global Bioreactors Market Forecast Report 2024-2035 with Key Players Profiles of Applikon Biotechnology, Bionet, Cytiva, Eppendorf, Merck, Sartorius, Solaris Biotech, Solida Biotech and LABAO

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--CDC'S ACIP Unanimously Recommends Merck's CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Appropriate Adults.

CDC'S ACIP Unanimously Recommends Merck's CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Appropriate Adults

News out of a Centers for Disease Control and Prevention meeting appeared to dim the commercial prospects of Merck's new pneumococcal vaccine.

Merck Stock Is Slipping. A CDC Committee Considers Pneumococcal Vaccines.

Merck stock tumbled under its 50-day moving average Thursday after the FDA rejected its Daiichi Sankyo-partnered cancer drug.

Dow Jones Powerhouse Merck Dives On Surprise FDA Rejection

The FDA's CRL to Merck (MRK) and its partner Daiichi Sankyo for the patritumab deruxtecan BLA is based on observations made on inspection of a third-party manufacturing facility.

Merck's (MRK) Lung Cancer Candidate Faces FDA Rejection

Amazon

American Express

Microsoft

Walmart

Three of the best Dow stocks are in bases with two breaking out, including newbie and emerging AI play Amazon.

These Are The Best Dow Jones Stocks Of 2024 Thus Far

The U.S. Food and Drug Administration declined to approve Merck and Japan-based Daiichi Sankyo's lung cancer treatment, which belongs to a lucrative class of cancer therapies that work like "guided missiles".

US FDA declines to approve Merck-Daiichi's 'guided missile' cancer drug

BASKING RIDGE, N.J. & RAHWAY, N.J.--(BUSINESS WIRE)--The U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) seeking accelerated approval of Daiichi Sankyo (TSE: 4568) and Merck's (known as MSD outside of the United States and Canada) (NYSE: MRK) patritumab deruxtecan (HER3-DXd) for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) previously treated with.

Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer

RAHWAY, N.J.--(BUSINESS WIRE)--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), announced today the U.S. Department of Agriculture (USDA) approval of NOBIVAC® NXT Canine Flu H3N2, a next-level solution to help safeguard dogs against the ongoing threat of canine influenza. The product is expected to be available at veterinary clinics and hospitals nationwide late this summer. Merck Animal H.

USDA Approves Merck Animal Health's NOBIVAC® NXT Canine Flu H3N2 – The First and Only RNA-Particle Technology Vaccine for Canine Influenza

China's National Drug Administration has granted Merck's KEYTRUDA therapy a licence for first-line treatment of certain stomach cancer patients in the country.

China grants licence to Merck's KEYTRUDA for stomach cancer treatment

Merck & Co's Frankfurt-listed shares fell 10% on Tuesday morning after the pharmaceutical giant said it had decided to call off a Phase III trial of its cancer drug Xevinapant, in an unexpected turn that threatens to undermine confidence in the company's research abilities.

Merck shares drop 10% as pharma giant scraps trial of promising cancer drug

Broadcom

Alibaba

Coherent Corp

Hess

NVIDIA

Pfizer

Taiwan Semiconductor Manufacturing

Artificial intelligence (AI) has the potential to add nearly $16 trillion to the global economy by the turn of the decade. Eight top-tier billionaires sent shares of Nvidia to the chopping block in the March-ended quarter.

Forget Nvidia: Prominent Billionaires Are Selling It in Favor of These 7 Top-Notch Stocks

Merck (MRK) closed the most recent trading day at $132.96, moving +1.71% from the previous trading session.

Merck (MRK) Increases Despite Market Slip: Here's What You Need to Know

DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced the discontinuation of the Phase III randomized TrilynX study evaluating xevinapant plus chemoradiotherapy (CRT) in patients with unresected locally advanced squamous cell carcinoma of the head and neck (LA SCCHN). The decision follows a pre-planned interim analysis performed by the study's Independent Data Monitoring Committee, which found that the trial would be unlikely to meet its primary o.

Merck Provides Update on Phase III TrilynX Study in Locally Advanced Head and Neck Cancer

AstraZeneca

There are multiple reasons to consider exposure to pharmaceutical stocks for the long-term portfolio. First, pharma stocks have a low-beta and provide and help in reducing the overall beta of a portfolio that's overweight growth stocks.

3 Undervalued Pharma Stocks to Buy for Dividends and Capital Gains

We believe that the computing behemoth IBM (NYSE: IBM) is currently a better pick over the pharmaceuticals giant Merck (NYSE: MRK). The decision to invest often comes down to finding the best stocks within the scope of certain characteristics that suit an investment style.

With Robust AI Prospects Is IBM A Better Pick Over Merck Stock Within The Dow Index?

Intellia Therapeutics

Arrowhead Pharmaceuticals

Verona Pharma

X4 Pharmaceuticals Inc

Biotech stocks are high-risk, high-return opportunities that are under the mercy of several make-or-break catalysts, most of which are binary events. It pays to remain cognizant of the timing of these catalysts and which way they will likely pan out.

5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More

Pfizer currently dominates the market for pneumococcal vaccines. Merck aims to change that.

Merck Prepares to Take on Pfizer After Pneumococcal Vaccine Approval

The U.S. Food and Drug Administration (FDA) approved Merck & Co Inc's  (NYSE:MRK) next-generation vaccine to protect adults against the pneumococcal disease.

Merck Stock Edges Higher on FDA Vaccine Approval

Merck's (MRK) 21-valent pneumococcal conjugate vaccine, Capvaxive/V116, becomes the first PCV specifically designed for adults to be approved by the FDA.

Merck's (MRK) 21-Valent Pneumococcal Jab Gets FDA Approval

Merck said on Monday the U.S. Food and Drug Administration has approved its next-generation vaccine to protect adults against pneumococcal disease.

News for Merck Stock (MRK)